The neural stem-cell marker CD24 is specifically upregulated in IDH-mutant glioma
Background: Malignant gliomas have disproportionally high morbidity and mortality. Heterozygous mutations in the isocitrate dehydrogenase 1 (IDH1) gene are most common in glioma, resulting in predominantly arginine to histidine substitution at codon 132. Because IDH1R132H requires a wild-type allele...
Main Authors: | Patricia D.B. Tiburcio, Mary C. Locke, Srividya Bhaskara, Mahesh B. Chandrasekharan, L. Eric Huang |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-10-01
|
Series: | Translational Oncology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523320303119 |
Similar Items
-
Metabolic reprogramming in mutant IDH1 glioma cells.
by: Jose L Izquierdo-Garcia, et al.
Published: (2015-01-01) -
Mutant IDH1 Promotes Glioma Formation In Vivo
by: Beatrice Philip, et al.
Published: (2018-05-01) -
Wild-Type IDH1 and Mutant IDH1 Opposingly Regulate Podoplanin Expression in Glioma
by: Chao Sun, et al.
Published: (2020-04-01) -
Early Noninvasive Metabolic Biomarkers of Mutant IDH Inhibition in Glioma
by: Marina Radoul, et al.
Published: (2021-02-01) -
Methylation of PD-1 Promoter Gene as New Prognostic Marker for IDH Mutant Low-Grade Glioma?
by: Christine Marosi
Published: (2018-03-01)